BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11267487)

  • 1. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
    Molmenti EP; Nagata D; Roden J; Squires R; Molmenti H; Casey D; Fasola C; Lopez MJ; Winick N; McPhail W; D'Amico L; Goldstein R; Levy M; Fasola C; Andersen J; Klintmalm G
    Transplant Proc; 2001; 33(1-2):1727. PubMed ID: 11267487
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine.
    Zajicek A; Esquivel C; Millan M; Cox K; Berquist R; Berquist W
    Transplant Proc; 2002 Aug; 34(5):1976-8. PubMed ID: 12176653
    [No Abstract]   [Full Text] [Related]  

  • 4. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low incidence of posttransplant lymphoproliferative disease in children treated with low-dose immunosuppression after liver transplantation.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    Transplant Proc; 2002 Aug; 34(5):1961-2. PubMed ID: 12176645
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoral is superior to FK 506 in liver transplantation.
    Levy GA
    Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation.
    Granot E; Doron D; Morag R
    Transplant Proc; 2000 Jun; 32(4):706-7. PubMed ID: 10856551
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
    Eshraghian A; Imanieh MH; Dehghani SM; Nikeghbalian S; Shamsaeefar A; Barshans F; Kazemi K; Geramizadeh B; Malek-Hosseini SA
    World J Gastroenterol; 2017 Feb; 23(7):1224-1232. PubMed ID: 28275302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group.
    Pirsch JD
    Transplantation; 1999 Oct; 68(8):1203-5. PubMed ID: 10551653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine.
    Andries S; Casamayou L; Sempoux C; Burlet M; Reding R; Bernard Otte J; Buts JP; Sokal E
    Transplantation; 2001 Jul; 72(2):267-72. PubMed ID: 11477351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection.
    Reyes J; Jain A; Mazariegos G; Kashyap R; Green M; Iurlano K; Fung J
    Transplantation; 2000 Jun; 69(12):2573-80. PubMed ID: 10910279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients.
    Wiederkehr JC; Coelho IM; Avilla SG; e Silva EM; Schuller S; Ouno DD; Wiederkehr BA; Polimeni M
    Transplant Proc; 2010 Mar; 42(2):521-2. PubMed ID: 20304183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
    Praghakaran K; Wise B; Chen A; Schwarz K; Colombani P
    J Pediatr Surg; 1999 Jan; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.
    Kizilbash SJ; Rheault MN; Bangdiwala A; Matas A; Chinnakotla S; Chavers BM
    Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28371243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant lymphoproliferative disorders and other malignancies after pediatric intestinal transplantation: incidence, clinical features and outcome.
    Ramos E; Hernández F; Andres A; Martínez-Ojinaga E; Molina M; Sarría J; Lopez-Santamaria M; Prieto G
    Pediatr Transplant; 2013 Aug; 17(5):472-8. PubMed ID: 23730927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Posttransplant Lymphoproliferative Disorder in Pediatric Patients With a Liver Transplant.
    Aliakbarian M; Dehghani SM; Geramizadeh B; Nikeghbalian S; Kasiri K; Kazemi K; Shamsaeefar A; Bahador A; Malekhosseini SA
    Exp Clin Transplant; 2015 Oct; 13(5):426-9. PubMed ID: 25232740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads.
    Kamei H; Ito Y; Kawada J; Ogiso S; Onishi Y; Komagome M; Kurata N; Ogura Y
    Transpl Infect Dis; 2018 Aug; 20(4):e12911. PubMed ID: 29677384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.